ASCO24: Moderna’s cancer vaccine poised to transform melanoma landscape – Pharmaceutical Technology
At the American Society of Clinical Oncology (ASCO) Annual Meeting, 31 May to 4 June, three-year follow-up results were presented for the KEYNOTE-942 study (NCT03897881)